L–carnitine in metabolic dysfunction-associated steatotic liver disease: mechanisms and therapeutic potential
Frontiers in Nutrition · 31.03.2026 · 13
DOI: 10.3389/fnut.2026.1804917 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 31.03.2026. Verfasst von Caili Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over one-third of the global population, representing one of the most prevalent chronic liver diseases. The escalating global prevalence of MASLD is concerning, as the disease can progress silently to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Furthermore, MASLD is independently associated with increased risks of cardiovascular disease, chronic kidney disease, and various extrahepatic malignancies, posing a substantial threat to public health. Consequently, developing effective preventive and therapeutic strategies is crucial. L-carnitine is a well-established dietary supplement that demonstrates potential to mitigate the onset and progression of MASLD. Its proposed mechanisms include the enhancement of lipid metabolism, improvement of insulin sensitivity, stabilization of hepatocyte function, and reduction of inflammation, fibrosis, and tumorigenesis. This comprehensive review synthesizes recent advances in the molecular mechanisms through which L-carnitine influences MASLD pathogenesis and critically evaluates its therapeutic potential in MASLD prevention, management, and prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Nutrition, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zitieren
APA
Chen, C., Zou, J., Li, L., Liu, S., Liu, Z., Yao, L., Peng, P., Liang, J., Chen, Z., Huang, H., & Huang, J. (2026). L–carnitine in metabolic dysfunction-associated steatotic liver disease: mechanisms and therapeutic potential. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1804917
Vancouver
Chen C, Zou J, Li L, Liu S, Liu Z, Yao L, et al. L–carnitine in metabolic dysfunction-associated steatotic liver disease: mechanisms and therapeutic potential. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1804917
BibTeX
@article{Chen2026,
author = {Chen, Caili and Zou, Jun and Li, Liwei and Liu, Shikai and Liu, Zheng and Yao, Li and Peng, Peng and Liang, Jingrong and Chen, Zhijian and Huang, Huijian and Huang, Jiean},
title = {L–carnitine in metabolic dysfunction-associated steatotic liver disease: mechanisms and therapeutic potential},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1804917}
}
EUVIMED